Do you want to read an article? Please log in or register.
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
Lung, Respiratory and Thoracic Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
★ 1
Recommended by
Alexander Meisel, Faculty Member
J Clin Oncol.
Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR
doi: 10.1200/JCO.20.01149.Visit the original publication at ncbi.nlm.nih.gov
Lung, Respiratory and Thoracic Cancer
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial
JAMA Oncol.
Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H
doi: 10.1001/jamaoncol.2020.1250.
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
Int J Cancer.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
doi: 10.1002/ijc.30691.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer (Auckl)
Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H
doi: 10.2147/LCTT.S318007
Lung, Respiratory and Thoracic Cancer
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Crit Rev Oncol Hematol.
Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, Bertolini F, Barbieri F, Cascinu S
doi: 10.1016/j.critrevonc.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
Lung Cancer.
Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K1, Hisada T
doi: 10.1016/j.lungcan.2018.10.014.
Lung, Respiratory and Thoracic Cancer
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
Expert Rev Anticancer Ther.
Brückl W, Tufman A, Huber RM
doi: 10.1080/
Lung, Respiratory and Thoracic Cancer
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Lung Cancer.
Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N
doi: 10.1016/j.lungcan.2019.04.014.